Privi Speci. (PRIVISCL)

FairStock Score: 48/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Privi Speci. as a specialty-chemicals business with a decent franchise but not a bargain. At ₹3,482 and ₹13,602 Cr market cap, I am paying 40.16 times earnings and 9.63 times book—hardly Graham's margin of safety. The positives are real: ROE of 32.37%, ROCE of 16.42%, promoter holding of 60.60%, a Piotroski F-Score of 7/9, and profit growth of 22.68% versus sales growth of 7.05%. Latest quarter sales of ₹605 Cr and net profit of ₹75 Cr show profitability, and PEG of 0.80 hints the P/E may be supported if that profit growth persists. But I must weigh the weak long-term top line: five-year revenue CAGR is only 5.19%, and free cash flow is negative ₹13 Cr. Debt/equity of 0.74 is not dangerous, but it is not a fortress balance sheet. Dividend yield of 0.29% gives little comfort while waiting. The stock trades near the top of its 52-week range of ₹2,470–₹3,785, so optimism is already reflected. Specialty chemicals can have switching costs and customer stickiness, but I cannot verify a wide moat from these numbers alone. FairStock Score of 48/100 says mixed. For a Buffett-style purchase, I want a wonderful business at a fair price; here the business looks good but the price asks for continued profit execution. I would watch FCF turning positive, revenue CAGR improving, and ROCE rising beyond 16.42%. Until then, it is a watchlist candidate, not a margin-of-safety buy.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer